scholarly journals Epilepsziával szövődött terhesség preconceptionalis és perinatalis kihívásai

2016 ◽  
Vol 157 (15) ◽  
pp. 563-568
Author(s):  
Melinda Vanya ◽  
Iván Devosa ◽  
Délia Szok ◽  
György Bártfai
Keyword(s):  
Clinical Practice ◽  
Antiepileptic Drugs ◽  
Pregnancy Outcome ◽  
Epileptic Seizures ◽  
Teratogenic Effect ◽  
Daily Clinical Practice ◽  
Careful Attention ◽  
Antiepileptic Therapy ◽  
Reproductive Aged Women ◽  
The Impact

Reproductive-aged women with epilepsy may present a number of specific issues to be managed in daily clinical practice. The impact of epileptic seizures and antiepileptic therapy on pregnancy outcome and the risk of teratogenicity should be minimized, which require careful attention and cooperation between obstetric gynecologyst and neurologist. The aim of the present paper is to review the impact of epilepsy attack on fetus and the pathomechanism and teratogenic effect of antiepileptic drugs. Orv. Hetil., 2016, 157(15), 563–568.

scholarly journals Is there a universal drug for epilepsy?

2018 ◽  
Vol 10 (2) ◽  
pp. 95-103 ◽  
Author(s):  
S. G. Burd ◽  
A. V. Lebedeva ◽  
Yu. V. Rubleva ◽  
M. B. Mironov ◽  
T. M. Krasilshikova
Keyword(s):  
Antiepileptic Drugs ◽  
Epileptic Seizures ◽  
Juvenile Myoclonic Epilepsy ◽  
Myoclonic Epilepsy ◽  
Complex Case ◽  
Diagnostic Process ◽  
High Efficacy ◽  
Antiepileptic Therapy

The article reviews the use of antiepileptic drugs in various forms of epilepsy. We present a complex case of juvenile myoclonic epilepsy, the diagnostic process and antiepileptic therapy. Our own data and the results of others demonstrated a high efficacy and tolerability of valproate drugs, and a low aggravation potential in all types of epileptic seizures.

What Is the Impact of Biliary Intraductal Ultrasound in Daily Clinical Practice?

2009 ◽  
Vol 69 (5) ◽  
pp. AB147-AB148
Author(s):  
Tiing Leong Ang ◽  
Teo Eng Kiong ◽  
Kwong Ming Fock
Keyword(s):  
Clinical Practice ◽  
Daily Clinical Practice ◽  
The Impact

Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 323-323 ◽  
Author(s):  
Orazio Caffo ◽  
Stefania Kinspergher ◽  
Francesca Maines ◽  
Sveva Macrini ◽  
Antonello Veccia
Keyword(s):  
Clinical Practice ◽  
Performance Status ◽  
Treated Group ◽  
Daily Clinical Practice ◽  
Consecutive Series ◽  
First Line ◽  
Radium 223 ◽  
Group A ◽  
Group B ◽  
The Impact

323 Background: Until few years ago, docetaxel (DOC) was the only agent able to significantly prolong overall survival (OS) of mCRPC pts: at the time of disease progression, other drugs without any survival benefit (mitoxantrone, vinorelbine, cyclophosphamide) or DOC re-challenge (DOC-re) in selected cases could be proposed. In the last years several NAs [abiraterone (AA), cabazitaxel (CAB), enzalutamide (ENZ), radium 223(RA223)] have been introduced in the clinical practice since they demonstrated an OS improvement. Moreover, a hypothetical cumulative OS advantage could derive from their sequential use. The present report is aimed to assess the impact on NAs on mCRPC pts’ OS in the daily clinical practice. Methods: We retrospectively evaluated all mCRPC pts treated in our Institution from 02/2002 to 06/2015 and recorded their medical history, anticancer treatments and survival outcomes. For the purpose of the present study, we consider pts who never received at least one NA (group A) and pts who received at least one NA (group B). To avoid selection bias due to a fast performance status worsening preventing further treatments, we consider only pts who received at least one agent after first line progression. For the OS analysis we considered the start of mCRPC first line. Results: We selected a consecutive series of 212 pts: 80 not treated (Group A) and 132 treated (Group B) with NAs. In the Group A 50 pts received first-line DOC followed by DOC-re only, while the remaining 30 pts received also agents different than DOC. In the group B 78, 35, and 19 pts received one, two, and three NAs, respectively. Group A pts were significantly younger and had higher baseline levels of PSA and lactate dehydrogenase (LDH). The OS was significantly longer in Group B than in Group A (36.0 vs 19.6 mos, p < 0.0001). The impact of NAs use on OS was confirmed at the multivariate analysis comprising the other factors which significantly affected OS (hemoglobin, LDH, alkaline phosphatase, pain, performance status, PSA). Conclusions: Although the limitation due to its retrospective nature, our analysis confirms that the introduction of NAs in the daily clinical practice led to an OS improvement.

Multiple Sclerosis Progression Discussion Tool: Usability and Usefulness in Clinical Practice (Preprint)

2021 ◽  
Author(s):  
Tjalf Ziemssen ◽  
Gavin Giovannoni ◽  
Enrique Alvarez ◽  
Virender Bhan ◽  
Carrie Hersh ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Practice ◽  
Cognitive Function ◽  
Disease Progression ◽  
Online Survey ◽  
Likert Scale ◽  
Daily Clinical Practice ◽  
Daily Activities ◽  
Final Questionnaire ◽  
The Impact

BACKGROUND A digital tool (Multiple Sclerosis Progression Discussion tool, MSProDiscuss) was developed to facilitate a discussion between a healthcare professional (HCP) and patient in evaluating early, subtle signs of multiple sclerosis (MS) disease progression. OBJECTIVE To report findings on the usability and usefulness testing of the MSProDiscuss tool in the real-world clinical setting. METHODS In this cross sectional, online survey, HCPs across 34 countries completed an initial individual questionnaire (comprising 7 questions on comprehensibility, usability and usefulness after using MSProDiscuss during each patient consultation) and a final questionnaire (comprising 13 questions on comprehensibility, usability and usefulness, and integration and adoption into clinical practice to capture their overall experience on using the tool). Responses were provided on a 5-point Likert scale. All analyses were descriptive, and no statistical comparisons were made. RESULTS In total, 301 HCPs tested the tool in 6974 MS patients, of which 77% were relapsing remitting MS patients including those suspected to be transitioning to secondary progressive MS. The time taken to complete MSProDiscuss was 1-4 minutes in 97% (initial) to 98% (final) of the cases. In 94% (initial) to 97% (final) cases, HCPs agreed (4 or 5 on the Likert scale) that patients were able to comprehend the questions from the tool. HCPs were willing to use the tool again in the same patient 91% (initial) of the cases. MSProDiscuss was useful in discussing MS symptoms and their impact on daily activities (88% initial and 92% final) and cognitive function (79% for both initial and final) and in discussing progression in general (88% initial and 90% final). While completing the final questionnaire, 95% of HCPs agreed that the questions were similar to those asked in regular consultation and the tool helped to better understand the impact of MS symptoms on daily activities (91%) and cognitive function (80%). Overall, 92% of the HCPs would recommend MSProDiscuss to a colleague, and 86% are willing to integrate it into their clinical practice. CONCLUSIONS MSProDiscuss is a usable and useful tool to facilitate a physician-patient discussion on disease progression in daily clinical practice. Most HCPs agreed that the tool is easy to use and were willing to integrate MSProDiscuss into their daily clinical practice.

The impact of gender on asthma in the daily clinical practice

2018 ◽  
Vol 130 (2) ◽  
pp. 271-273 ◽  
Author(s):  
Giorgio Ciprandi ◽  
Fabio Gallo
Keyword(s):  
Clinical Practice ◽  
Daily Clinical Practice ◽  
The Impact

Translating Principles of Speech Science to Clinical Practice: Current and Future Trends in Craniofacial Disorders

2008 ◽  
Vol 18 (1) ◽  
pp. 31-40 ◽  
Author(s):  
David J. Zajac
Keyword(s):  
Clinical Practice ◽  
Speech Intelligibility ◽  
Current Practice ◽  
Computer Assisted ◽  
Behavioral Management ◽  
Single Word ◽  
Future Directions ◽  
Speech Science ◽  
The Impact ◽  
Opinion Article

Abstract The purpose of this opinion article is to review the impact of the principles and technology of speech science on clinical practice in the area of craniofacial disorders. Current practice relative to (a) speech aerodynamic assessment, (b) computer-assisted single-word speech intelligibility testing, and (c) behavioral management of hypernasal resonance are reviewed. Future directions and/or refinement of each area are also identified. It is suggested that both challenging and rewarding times are in store for clinical researchers in craniofacial disorders.

Sign in / Sign up

Export Citation Format

Share Document